Ocrelizumab
Ocrelizumab
Ocrelizumab (pronounced oh-kreh-LIZ-yoo-mab) is a monoclonal antibody designed for the treatment of multiple sclerosis (MS). It is marketed under the brand name Ocrevus by Genentech.
Etymology
The name "Ocrelizumab" is derived from its function and structure. The prefix "Ocre" is an arbitrary syllable, "li" indicates its human origin, "zu" denotes that it targets the immune system, and "mab" is a common suffix for monoclonal antibodies.
Usage
Ocrelizumab is used primarily in the treatment of relapsing and primary progressive forms of multiple sclerosis. It works by depleting a type of B cell that contributes to the MS disease process.
Dosage and Administration
Ocrelizumab is administered by intravenous infusion every six months, after an initial dose that is split into two infusions two weeks apart.
Side Effects
Common side effects of Ocrelizumab include infection, fatigue, and infusion-related reactions. Serious side effects may include increased risk of certain types of cancer and hepatitis B reactivation.
Related Terms
External links
- Medical encyclopedia article on Ocrelizumab
- Wikipedia's article - Ocrelizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski